Reduced cannabinoid 2 receptor activity increases susceptibility to induced seizures in mice

Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome

(2019) Jennifer C. Wong et al.   Annals of Clinical and Translational Neurology

CB2 receptor antibody signal specificity: correlations with the use of partial CB2-knockout mice and anti-rat CB2 receptor antibodies

(2018) Hai-ying Zhang et al.   ACTA PHARMACOLOGICA SINICA

Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer’s disease

(2018) Alicia López et al.   Journal of Neuroinflammation

Pharmacological characterization of the cannabinoid receptor 2 agonist, β-caryophyllene on seizure models in mice

(2018) Jana Tchekalarova et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Selective targeting of Scn8a prevents seizure development in a mouse model of mesial temporal lobe epilepsy

(2018) Jennifer C. Wong et al.   Scientific Reports

CB2 Cannabinoid Receptor Agonist Ameliorates Alzheimer-Like Phenotype in AβPP/PS1 Mice

(2018) Ester Aso et al.   JOURNAL OF ALZHEIMERS DISEASE

The spatiotemporal expression changes of CB2R in the hippocampus of rats following pilocarpine-induced status epilepticus

(2018) Qiong Wu et al.   EPILEPSY RESEARCH

Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats

(2017) Megan N. Huizenga et al.   EPILEPSIA

Cannabinoids for epilepsy: What do we know and where do we go?

(2017) Martin J. Brodie et al.   EPILEPSIA

Cannabinoid receptor 1/2 double-knockout mice develop epilepsy

(2017) Shane Rowley et al.   EPILEPSIA

Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection

(2017) Evan C. Rosenberg et al.   EPILEPSY & BEHAVIOR

Pharmacology of cannabinoids in the treatment of epilepsy

(2017) Tyler E. Gaston et al.   EPILEPSY & BEHAVIOR

Cannabinoids in treatment-resistant epilepsy: A review

(2017) Brooke K. O'Connell et al.   EPILEPSY & BEHAVIOR

Early-life febrile seizures worsen adult phenotypes in Scn1a mutants

(2017) Stacey B.B. Dutton et al.   EXPERIMENTAL NEUROLOGY

Immunopathology in drug resistant mesial temporal lobe epilepsy with different types of hippocampal sclerosis

(2017) F. Irsel Tezer et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Activation of cannabinoid receptor type 2 attenuates surgery-induced cognitive impairment in mice through anti-inflammatory activity

(2017) Lingling Sun et al.   Journal of Neuroinflammation

SCN3A deficiency associated with increased seizure susceptibility

(2017) Tyra Lamar et al.   NEUROBIOLOGY OF DISEASE

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

(2017) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome

(2017) Joshua S. Kaplan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity

(2017) Marjolein Soethoudt et al.   Nature Communications

Anticonvulsant activity of β-caryophyllene against pentylenetetrazol-induced seizures

(2016) Cleide Correia de Oliveira et al.   EPILEPSY & BEHAVIOR

The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats

(2016) Cristiane R. de Carvalho et al.   EPILEPSY RESEARCH

Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease

(2016) Ruth M. Concannon et al.   EXPERIMENTAL NEUROLOGY

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

(2016) Orrin Devinsky et al.   LANCET NEUROLOGY

Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus

(2016) A. Vanessa Stempel et al.   NEURON

Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease

(2016) Yolanda Gómez-Gálvez et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Cannabinoid Type-2 Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke

(2016) Isabel Bravo-Ferrer et al.   STROKE

Crucial Roles of the Endocannabinoid 2-Arachidonoylglycerol in the Suppression of Epileptic Seizures

(2016) Yuki Sugaya et al.   Cell Reports

Huperzine A Provides Robust and Sustained Protection against Induced Seizures in Scn1a Mutant Mice

(2016) Jennifer C. Wong et al.   Frontiers in Pharmacology

The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects

(2015) Jan van Amsterdam et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus

(2015) Y. Li et al.   NEUROSCIENCE

Cannabinoids and Epilepsy

(2015) Evan C. Rosenberg et al.   Neurotherapeutics

Expression Analysis of CB2-GFP BAC Transgenic Mice

(2015) Anne-Caroline Schmöle et al.   PLoS One

Time-Dependent Protection of CB2 Receptor Agonist in Stroke

(2015) Seong-Jin Yu et al.   PLoS One

Regulatory role of the cannabinoid CB2receptor in stress-induced neuroinflammation in mice

(2014) S Zoppi et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

(2014) Orrin Devinsky et al.   EPILEPSIA

Modulation of Pilocarpine-Induced Seizures by Cannabinoid Receptor 1

(2014) Rebecca L. Kow et al.   PLoS One

What we know and do not know about the cannabinoid receptor 2 (CB2)

(2014) Anna Maria Malfitano et al.   SEMINARS IN IMMUNOLOGY

Antibody testing for brain immunohistochemistry: Brain immunolabeling for the cannabinoid CB2 receptor

(2013) Jean-Ha Baek et al.   JOURNAL OF NEUROSCIENCE METHODS

A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury

(2012) Peter S. Amenta et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities

(2012) R. G. Pertwee   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors

(2012) F. S. den Boon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acute Effects of a Selective Cannabinoid-2 Receptor Agonist on Neuroinflammation in a Model of Traumatic Brain Injury

(2011) Melanie B. Elliott et al.   JOURNAL OF NEUROTRAUMA

Cannabinoid Type 2 Receptor Activation Downregulates Stroke-Induced Classic and Alternative Brain Macrophage/Microglial Activation Concomitant to Neuroprotection

(2011) Juan G. Zarruk et al.   STROKE

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Altered Function of theSCN1AVoltage-gated Sodium Channel Leads to γ-Aminobutyric Acid-ergic (GABAergic) Interneuron Abnormalities

(2010) Melinda S. Martin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Species differences in cannabinoid receptor 2 (CNR2gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands

(2009) Q.-R. Liu et al.   GENES BRAIN AND BEHAVIOR

Self-modulation of neocortical pyramidal neurons by endocannabinoids

(2009) Silvia Marinelli et al.   NATURE NEUROSCIENCE

Temperature- and age-dependent seizures in a mouse model of severe myoclonic epilepsy in infancy

(2009) J. C. Oakley et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA